148 related articles for article (PubMed ID: 27879989)
1. CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.
Kwiecinska A; Tsesmetzis N; Ghaderi M; Kis L; Saft L; Rassidakis GZ
Br J Haematol; 2018 Mar; 180(5):744-748. PubMed ID: 27879989
[No Abstract] [Full Text] [Related]
2. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
6. PD-1 is highly expressed by neoplastic B-cells in Richter transformation.
Behdad A; Griffin B; Chen YH; Ma S; Kelemen K; Lu X; Chen QC
Br J Haematol; 2019 Apr; 185(2):370-373. PubMed ID: 30028010
[No Abstract] [Full Text] [Related]
7. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.
Juárez-Salcedo LM; Sandoval-Sus J; Sokol L; Chavez JC; Dalia S
Crit Rev Oncol Hematol; 2017 May; 113():52-62. PubMed ID: 28427522
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma.
Yanagida E; Miyoshi H; Takeuchi M; Shimono J; Nakashima K; Yamada K; Kawamoto K; Moritsubo M; Shimasaki Y; Inoue K; Imamoto T; Furuta T; Kohno K; Ohshima K
Hematol Oncol; 2022 Oct; 40(4):530-540. PubMed ID: 35122292
[TBL] [Abstract][Full Text] [Related]
11. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
12. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Suzuki Y; Sakakibara A; Shimada K; Shimada S; Ishikawa E; Nakamura S; Kato S; Takahara T; Asano N; Satou A; Kohno K
Pathol Int; 2019 Jan; 69(1):13-20. PubMed ID: 30601579
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
15. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and tumor-associated macrophages in de novo DLBCL.
McCord R; Bolen CR; Koeppen H; Kadel EE; Oestergaard MZ; Nielsen T; Sehn LH; Venstrom JM
Blood Adv; 2019 Feb; 3(4):531-540. PubMed ID: 30770362
[TBL] [Abstract][Full Text] [Related]
17. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study.
Kannan S; O'Connor GM; Bakker EY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067485
[TBL] [Abstract][Full Text] [Related]
20. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Kataoka K; Shiraishi Y; Takeda Y; Sakata S; Matsumoto M; Nagano S; Maeda T; Nagata Y; Kitanaka A; Mizuno S; Tanaka H; Chiba K; Ito S; Watatani Y; Kakiuchi N; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Itonaga H; Imaizumi Y; Totoki Y; Munakata W; Nakamura H; Hama N; Shide K; Kubuki Y; Hidaka T; Kameda T; Masuda K; Minato N; Kashiwase K; Izutsu K; Takaori-Kondo A; Miyazaki Y; Takahashi S; Shibata T; Kawamoto H; Akatsuka Y; Shimoda K; Takeuchi K; Seya T; Miyano S; Ogawa S
Nature; 2016 Jun; 534(7607):402-6. PubMed ID: 27281199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]